DE602006006308D1 - Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten - Google Patents

Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten

Info

Publication number
DE602006006308D1
DE602006006308D1 DE602006006308T DE602006006308T DE602006006308D1 DE 602006006308 D1 DE602006006308 D1 DE 602006006308D1 DE 602006006308 T DE602006006308 T DE 602006006308T DE 602006006308 T DE602006006308 T DE 602006006308T DE 602006006308 D1 DE602006006308 D1 DE 602006006308D1
Authority
DE
Germany
Prior art keywords
glycol
poloxamer
meroxapol
tensid
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602006006308T
Other languages
German (de)
English (en)
Inventor
Geoffrey Robert Owen
Amy C Brooks
Gustav Graff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of DE602006006308D1 publication Critical patent/DE602006006308D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602006006308T 2005-05-10 2006-05-08 Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten Expired - Lifetime DE602006006308D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67933205P 2005-05-10 2005-05-10
PCT/US2006/017606 WO2006121963A2 (en) 2005-05-10 2006-05-08 Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders

Publications (1)

Publication Number Publication Date
DE602006006308D1 true DE602006006308D1 (de) 2009-05-28

Family

ID=37081695

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006006308T Expired - Lifetime DE602006006308D1 (de) 2005-05-10 2006-05-08 Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten

Country Status (19)

Country Link
US (1) US20060257487A1 (https=)
EP (1) EP1885336B1 (https=)
JP (1) JP4968954B2 (https=)
KR (1) KR20080011310A (https=)
CN (1) CN101175475B (https=)
AT (1) ATE428401T1 (https=)
AU (1) AU2006244244B2 (https=)
BR (1) BRPI0609227A2 (https=)
CA (1) CA2607608A1 (https=)
CY (1) CY1109117T1 (https=)
DE (1) DE602006006308D1 (https=)
DK (1) DK1885336T3 (https=)
ES (1) ES2322200T3 (https=)
MX (1) MX2007014083A (https=)
PL (1) PL1885336T3 (https=)
PT (1) PT1885336E (https=)
SI (1) SI1885336T1 (https=)
WO (1) WO2006121963A2 (https=)
ZA (1) ZA200709251B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1906916T3 (da) * 2005-05-10 2009-01-19 Alcon Inc Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
WO2008153746A1 (en) * 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
AU2010221438C1 (en) * 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
US20100234469A1 (en) * 2009-03-12 2010-09-16 Medichem, S.A. New Crystals Of A Benzoylbenzeneacetamide Derivative
PH12012501111A1 (en) * 2009-12-03 2016-09-09 Novartis Ag Carboxyvinyl polymer-containing nanoparticles suspensions
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
KR20140048218A (ko) 2011-06-28 2014-04-23 바이엘 헬스케어 엘엘씨 레고라페닙을 함유하는 국소 안과용 약학 조성물
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
GR1007906B (el) * 2012-03-22 2013-05-30 Φαρματεν Αβεε, Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013188283A1 (en) 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
WO2014160579A1 (en) * 2013-03-25 2014-10-02 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
MX383077B (es) * 2013-07-22 2025-03-13 Novel Drug Solutions Llc Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio.
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN104706579A (zh) * 2015-03-12 2015-06-17 广州仁恒医药科技有限公司 一种夫西地酸滴眼液及其制备方法
US10508134B2 (en) 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
KR102356603B1 (ko) * 2021-08-05 2022-02-08 지엘팜텍주식회사 안구건조증 치료를 위한 레코플라본 함유 점안 조성물
WO2023049809A1 (en) 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
CN114272207B (zh) * 2022-01-21 2023-04-11 山东诺明康药物研究院有限公司 一种纳米晶混悬滴眼液及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5364884A (en) * 1993-01-21 1994-11-15 Baylor College Of Medicine Arginine compounds as ocular hypotensive agents
US5631005A (en) * 1994-09-21 1997-05-20 Alcon Laboratories, Inc. Use of amidoamines in ophthalmic compositions
US5631004A (en) * 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
US6265444B1 (en) * 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
DK1203808T3 (da) * 1997-07-29 2005-01-31 Alcon Lab Inc Konditioneringsoplösninger til pleje af hårde kontaktlinser
US6037328A (en) * 1998-12-22 2000-03-14 Bausch & Lomb Incorporated Method and composition for rewetting and preventing deposits on contact lens
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
EP1249249A1 (en) * 2000-12-12 2002-10-16 Menicon Co., Ltd. Ophthalmic composition
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
JP2002332225A (ja) * 2001-05-09 2002-11-22 Lion Corp 眼科用組成物
ATE468107T1 (de) * 2001-11-01 2010-06-15 Yissum Res Dev Co Verfahren und zusammensetzung zur behandlung von trockenen augen
JP2003176228A (ja) * 2001-12-11 2003-06-24 Rohto Pharmaceut Co Ltd 液 剤
US20030133905A1 (en) * 2001-12-20 2003-07-17 Zhenze Hu Composition for treating contact lenses in the eye
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20040029771A1 (en) * 2002-02-28 2004-02-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
US20040115270A1 (en) * 2002-12-13 2004-06-17 Dharmendra Jani Absorption and controlled release of polyethers from hydrogel biomaterials
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
DK1906916T3 (da) * 2005-05-10 2009-01-19 Alcon Inc Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser

Also Published As

Publication number Publication date
PT1885336E (pt) 2009-05-07
SI1885336T1 (sl) 2009-08-31
ATE428401T1 (de) 2009-05-15
BRPI0609227A2 (pt) 2010-03-09
PL1885336T3 (pl) 2009-08-31
ZA200709251B (en) 2009-08-26
EP1885336B1 (en) 2009-04-15
DK1885336T3 (da) 2009-05-25
CY1109117T1 (el) 2014-07-02
EP1885336A2 (en) 2008-02-13
AU2006244244A1 (en) 2006-11-16
CN101175475B (zh) 2010-04-14
CA2607608A1 (en) 2006-11-16
US20060257487A1 (en) 2006-11-16
CN101175475A (zh) 2008-05-07
AU2006244244B2 (en) 2010-11-04
KR20080011310A (ko) 2008-02-01
MX2007014083A (es) 2008-02-07
WO2006121963A3 (en) 2007-03-22
JP2008540532A (ja) 2008-11-20
JP4968954B2 (ja) 2012-07-04
ES2322200T3 (es) 2009-06-17
WO2006121963A2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
DE602006006308D1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
CY1108676T1 (el) Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
NO20075136L (no) Nye liposompreparater
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
ATE535257T1 (de) Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin
NO20074850L (no) Oftalmologiske sammensetninger og anvendelse derav
BRPI0812494A2 (pt) Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
WO2008105507A1 (ja) 脊髄損傷治療薬剤
EA200602092A1 (ru) Способ и композиция для лечения ринита
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
WO2009074853A3 (en) Ophthalmic composition comprising phenylephrine
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
WO2008144690A3 (en) Compositions and methods for enhancing active agent absorption
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten
ATE477021T1 (de) 1,3,5-triazepin-dionen zur behandlung von malaria
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
ECSP034742A (es) Combinacion de brimonidina y timolol para uso oftalmologico topico

Legal Events

Date Code Title Description
8364 No opposition during term of opposition